scispace - formally typeset
A

Antonio Manzo

Researcher at University of Pavia

Publications -  92
Citations -  3594

Antonio Manzo is an academic researcher from University of Pavia. The author has contributed to research in topics: Rheumatoid arthritis & Arthritis. The author has an hindex of 29, co-authored 78 publications receiving 3016 citations. Previous affiliations of Antonio Manzo include Instituto de Medicina Molecular & Queen Mary University of London.

Papers
More filters
Journal ArticleDOI

Ectopic Lymphoid Structures Support Ongoing Production of Class-Switched Autoantibodies in Rheumatoid Synovium

TL;DR: It is demonstrated that FDC+ follicular units invariably express AID and are surrounded by ACPA-producing plasma cells, providing strong evidence that ectopic lymphoid structures in the RA synovium are functional and support autoantibody production.
Journal ArticleDOI

Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis.

TL;DR: The concept that, under inflammatory conditions, CXCL13 and CCL21 participate in lymphoid tissue microanatomical organization, attempting to recapitulate, in an aberrant lymphoid neogenetic process, their homeostatic and morphogenetic physiologic functions is supported.
Journal ArticleDOI

Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid-like structures in Sjögren's syndrome

TL;DR: The acquisition of lymphoid features byinflammatory foci in SS is critically associated with the enlargement of the inflammatory foci and with the expression of CXCL13 and CCL21 within the infiltrate, but is not associated with their expression by epithelial cells.
Journal ArticleDOI

Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study

TL;DR: This study demonstrated that RTX treatment results in a faster and more pronounced decrease of ESSDAI and other clinical parameters compared to DMARDs treatment, and showed that RTX is a safe and effective agent to be employed in pSS patients with systemic, extra-glandular involvement.